Who Is Andreas Met? Co-Founder of Ashland’s Satya Therapeutics and Head of the Psilocybin Alliance

Where Andreas Met Is Now

Andreas Met serves as a co-founder of Ashland's Satya Therapeutics and heads the Psilocybin Alliance trade group, according to reporting by Lucid News. He is also an active licensed psilocybin facilitator in Oregon, as reported by FinancialContent.

Operational and Facilitation Experience

Andreas Met possesses active experience across manufacturing, service center operations, and facilitation within the Oregon psilocybin services program, reported FinancialContent.

Through his work as a licensed psilocybin facilitator, Met has supported more than 250 clients through psilocybin-assisted therapeutic preparation, facilitation, and integration, according to FinancialContent.

Responses to Oregon Health Authority Fee Proposals

Andreas Met submitted a records request that led the Oregon Health Authority to release a document analyzing the financial impact of proposed fee increases, as reported by The Bend Bulletin. He stated that the agency released the analysis document only days before the public comment period ended, and he authored a letter on behalf of the Psilocybin Alliance criticizing the state's rulemaking process for lacking a fiscal analysis on fee increases.

Met described the Oregon Health Authority's fee hike proposal as deeply flawed, noting that he would have shut down the mushroom-growing operation of his business if faced with a $22,000 annual fee increase, according to Lucid News. After the Oregon Health Authority pulled the fee increases and decided to restart rulemaking, Met described the decision as "breathtaking" and stated regarding the pushback that the industry was fighting for its survival and came together, as documented by Lucid News and The Bend Bulletin.

Potency Standards and Policy Perspectives

Andreas Met participated in the Oregon Health Authority's Psilocybin Product Potency Workgroup, reported FinancialContent. In that context, Met stated that facilitators already account for both psilocybin and psilocin when determining dose strength, that variability in psilocin content exists in the regulated supply chain and must be addressed in policy design, and that simplifying potency guidance would help facilitators and clients make better decisions.

Met has also stated that facilitators have an obligation to ensure clients are ready before concluding a session, that clients need clarity regarding the effective strength of a psilocybin dose in a therapeutic context, and that the Oregon Health Authority has the opportunity to adopt a transparent, evidence-based approach safeguarding public safety and program viability, as noted by FinancialContent and Lucid News. Furthermore, Met and fellow Psilocybin Alliance members planned to lobby the Oregon legislature for a more sustainable funding model, while Met called on the Oregon Health Authority to be more transparent regarding the financial stability of the psilocybin program, as reported by The Bend Bulletin.

Frequently asked questions